Aridis Pharmaceuticals (ARDS) News Today $0.0001 0.00 (0.00%) (As of 09:33 AM ET) Add Compare Share Share Headlines Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Aridis Provides Corporate UpdateDecember 20, 2024 | globenewswire.comHorizon Tech Finance (NASDAQ:HRZN) Stock Quotes, Forecast and News SummaryOctober 11, 2024 | benzinga.comGenor Biopharma Holdings Limited (67N0.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comBreathing easier: Nature-inspired treatments could relieve acute respiratory distressAugust 3, 2024 | msn.comAridis Provides Corporate UpdateJune 24, 2024 | globenewswire.comAridis Pharmaceuticals Inc (ARDS)March 14, 2024 | uk.investing.comIrish Cup: Institute's quarter-final place confirmed as IFA rejects Ards protestFebruary 10, 2024 | bbc.co.ukAridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024December 15, 2023 | finance.yahoo.comAridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business UpdateNovember 3, 2023 | markets.businessinsider.comAridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business UpdateNovember 3, 2023 | finance.yahoo.comAridis Pharmaceuticals Inc ARDSNovember 1, 2023 | morningstar.comAridis Pharmaceuticals Stock (OTC:ARDS), Analyst Ratings, Price Targets, PredictionsOctober 22, 2023 | benzinga.comHC Wainwright & Co. Maintains Aridis Pharmaceuticals (ARDS) Buy RecommendationOctober 21, 2023 | msn.comFDA’s Qualified Infectious Disease Product Designation Bolsters Aridis Pharmaceuticals’ Investment Appeal: An Analyst’s Buy RecommendationOctober 20, 2023 | markets.businessinsider.comARDS Sep 2023 2.500 callSeptember 15, 2023 | finance.yahoo.comAridis Pharmaceuticals, Inc., Genetic Technologies Limited, and American Resources Corporation Interviews to Air on the RedChip Money Report(R) on Bloomberg TVSeptember 15, 2023 | finance.yahoo.comAridis Pharma (ARDS) Earnings Dates & ReportsAugust 21, 2023 | investing.comAridis Pharmaceuticals Announces $2 Million OfferingAugust 2, 2023 | finance.yahoo.comWhy Are Aridis Pharmaceuticals Shares Moving Higher Today?July 18, 2023 | finance.yahoo.comAridis Receives Agreement from the European Medicines Agency (EMA) on the Clinical Study Design and a Single Confirmatory Phase 3 Study of AR-301July 17, 2023 | finance.yahoo.comAridis (ARDS) Up on Receiving FDA's QIDP Designation for AR-301July 13, 2023 | finance.yahoo.comAridis’ AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA’s Qualified Infectious Diseases Product (QIDP) DesignationJuly 12, 2023 | finance.yahoo.comAridis Pharmaceuticals' AR-301 Eligible for Consideration under FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD)June 22, 2023 | marketwatch.comAridis Pharmaceuticals' AR-301 Eligible for Consideration under FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD)June 20, 2023 | finance.yahoo.comAridis Pharmaceuticals, Inc.: Aridis Pharmaceuticals Announces First Quarter 2023 Financial Results and Business UpdateJune 9, 2023 | finanznachrichten.deAridis Pharmaceuticals Announces First Quarter 2023 Financial Results and Business UpdateJune 8, 2023 | finance.yahoo.comAridis Pharmaceuticals Stock (NASDAQ:ARDS), Guidance and ForecastJune 1, 2023 | benzinga.comAridis Receives Agreement from the FDA on a Single Confirmatory Phase 3 Study of AR-301 and the Clinical Study DesignMay 31, 2023 | finance.yahoo.comAridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-QMay 25, 2023 | finance.yahoo.comAridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-KApril 26, 2023 | finance.yahoo.comBig pharma, small drug maker spar over pneumonia drug dealApril 3, 2023 | bizjournals.comAridis Provides Corporate UpdateMarch 31, 2023 | finance.yahoo.comAstraZeneca Axes Pneumonia Drug Pact With AridisMarch 29, 2023 | msn.comWhy Aridis Pharmaceuticals Shares Are DivingMarch 14, 2023 | msn.comAridis Pharmaceuticals Shares Tumble After Stock Offering >ARDSMarch 14, 2023 | marketwatch.comAridis (ARDS) Stock Up as Cystic Fibrosis Study Meets GoalsMarch 14, 2023 | msn.comAridis Pharmaceuticals Announces $2.28 Million Registered Direct Offering of Common StockMarch 14, 2023 | finance.yahoo.comAridis Skyrockets on Impressive Data In Cystic FibrosisMarch 13, 2023 | msn.comAridis stock surges ~35% as lung disease drug AR-501 meets main goal in mid-stage studyMarch 13, 2023 | msn.comWhy Aridis Pharmaceuticals Shares Are Soaring TodayMarch 13, 2023 | finance.yahoo.comAridis Shares Rally Premarket on Positive Phase 2a Cystic Fibrosis Study >ARDSMarch 13, 2023 | marketwatch.comAridis Meets Primary and Secondary Endpoints in Phase 2a Study of AR-501 in Cystic Fibrosis PatientsMarch 13, 2023 | finance.yahoo.comInterviews with Rail Vision, Aridis Pharmaceuticals, and Digital Ally to Air on Bloomberg U.S. on the RedChip Money ReportFebruary 17, 2023 | finanznachrichten.deWhen Will Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) Breakeven?February 15, 2023 | finance.yahoo.comIn virtuous cycle, foundation uses drug royalty riches to back new cystic fibrosis drug research in Bay AreaFebruary 6, 2023 | finance.yahoo.comHere's Why Aridis Pharmaceuticals (ARDS) Is a Great 'Buy the Bottom' Stock NowFebruary 1, 2023 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Ocuphire Pharma (OCUP), Aridis Pharmaceuticals (ARDS) and Acurx Pharmaceuticals (ACXP)January 27, 2023 | markets.businessinsider.comAridis stock slumps ~25% as antibody drug fails phase 3 trial in pneumoniaJanuary 26, 2023 | msn.comAridis Reports Top-Line Results of the Phase 3 Double-Blinded, Superiority Trial of AR-301 For the Treatment of Staphylococcus aureus Ventilator Associated Pneumonia (VAP)January 25, 2023 | finance.yahoo.comTrading was temporarily halted for "ARDS" at 04:01 PM with a stated reason of "News pending."January 25, 2023 | marketbeat.com Get Aridis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARDS and its competitors with MarketBeat's FREE daily newsletter. Email Address URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight. >> Register for the Workshop Now ARDS Media Mentions By Week ARDS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARDS News Sentiment▼0.000.64▲Average Medical News Sentiment ARDS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARDS Articles This Week▼00▲ARDS Articles Average Week Get Aridis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARDS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies NAVB News AMPE News EFTR News BTMDW News BCTXW News ENGNW News FBIOP News GOVXW News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARDS) was last updated on 1/2/2025 by MarketBeat.com Staff From Our Partners3 CENT Crypto to Explode December 16th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredI was wrong. Dead wrong. Something is stirring deep in Silicon Valley. My team and I have been watching the tech markets closely. ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aridis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aridis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
